Free Trial

STERIS (STE) Competitors

STERIS logo
$241.93 -3.13 (-1.28%)
Closing price 09/2/2025 03:59 PM Eastern
Extended Trading
$242.01 +0.08 (+0.03%)
As of 06:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

STE vs. BDX, IDXX, EW, RMD, DXCM, PODD, HOLX, BAX, GMED, and MASI

Should you be buying STERIS stock or one of its competitors? The main competitors of STERIS include Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), Edwards Lifesciences (EW), ResMed (RMD), DexCom (DXCM), Insulet (PODD), Hologic (HOLX), Baxter International (BAX), Globus Medical (GMED), and Masimo (MASI). These companies are all part of the "health care equipment" industry.

STERIS vs. Its Competitors

STERIS (NYSE:STE) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Becton, Dickinson and Company has higher revenue and earnings than STERIS. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STERIS$5.46B4.36$614.64M$6.5337.05
Becton, Dickinson and Company$20.18B2.67$1.71B$5.5633.83

STERIS currently has a consensus target price of $273.50, indicating a potential upside of 13.05%. Becton, Dickinson and Company has a consensus target price of $211.44, indicating a potential upside of 12.41%. Given STERIS's stronger consensus rating and higher probable upside, equities analysts clearly believe STERIS is more favorable than Becton, Dickinson and Company.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
STERIS
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75
Becton, Dickinson and Company
0 Sell rating(s)
7 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.36

In the previous week, Becton, Dickinson and Company had 9 more articles in the media than STERIS. MarketBeat recorded 26 mentions for Becton, Dickinson and Company and 17 mentions for STERIS. Becton, Dickinson and Company's average media sentiment score of 1.41 beat STERIS's score of 1.35 indicating that Becton, Dickinson and Company is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
STERIS
11 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Becton, Dickinson and Company
22 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

STERIS has a net margin of 11.61% compared to Becton, Dickinson and Company's net margin of 7.51%. Becton, Dickinson and Company's return on equity of 16.23% beat STERIS's return on equity.

Company Net Margins Return on Equity Return on Assets
STERIS11.61% 14.17% 9.25%
Becton, Dickinson and Company 7.51%16.23%7.46%

94.7% of STERIS shares are held by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are held by institutional investors. 1.1% of STERIS shares are held by company insiders. Comparatively, 0.4% of Becton, Dickinson and Company shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

STERIS pays an annual dividend of $2.28 per share and has a dividend yield of 0.9%. Becton, Dickinson and Company pays an annual dividend of $4.16 per share and has a dividend yield of 2.2%. STERIS pays out 34.9% of its earnings in the form of a dividend. Becton, Dickinson and Company pays out 74.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. STERIS has increased its dividend for 20 consecutive years and Becton, Dickinson and Company has increased its dividend for 53 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

STERIS has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Becton, Dickinson and Company has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500.

Summary

STERIS beats Becton, Dickinson and Company on 12 of the 19 factors compared between the two stocks.

Get STERIS News Delivered to You Automatically

Sign up to receive the latest news and ratings for STE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STE vs. The Competition

MetricSTERISMED INSTRUMENTS IndustryMedical SectorNYSE Exchange
Market Cap$24.14B$7.09B$5.74B$21.39B
Dividend Yield0.93%1.19%6.66%3.49%
P/E Ratio37.0525.3883.1929.00
Price / Sales4.3670.48532.4048.99
Price / Cash17.1922.4425.7018.29
Price / Book3.426.9611.095.30
Net Income$614.64M$174.83M$3.28B$997.87M
7 Day Performance-2.93%-0.12%-0.21%-0.47%
1 Month Performance6.72%3.72%8.31%6.49%
1 Year Performance-0.59%8.72%54.52%13.66%

STERIS Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STE
STERIS
4.9188 of 5 stars
$241.93
-1.3%
$273.50
+13.0%
+0.3%$24.14B$5.46B37.0517,787Positive News
Analyst Revision
BDX
Becton, Dickinson and Company
4.8897 of 5 stars
$194.70
-2.5%
$211.44
+8.6%
-22.4%$57.23B$20.18B13.9974,000Positive News
IDXX
IDEXX Laboratories
4.6708 of 5 stars
$641.35
-0.7%
$649.44
+1.3%
+32.9%$51.31B$3.90B53.4011,000Positive News
Short Interest ↓
EW
Edwards Lifesciences
4.402 of 5 stars
$80.92
-1.1%
$85.90
+6.2%
+16.9%$47.51B$5.69B11.6415,800Positive News
RMD
ResMed
4.7689 of 5 stars
$285.76
-2.7%
$274.83
-3.8%
+10.6%$41.84B$5.15B30.0510,600Positive News
Analyst Upgrade
DXCM
DexCom
4.9768 of 5 stars
$75.96
-7.7%
$99.89
+31.5%
+7.2%$29.79B$4.03B52.7510,300Positive News
PODD
Insulet
4.3037 of 5 stars
$329.00
-0.5%
$332.71
+1.1%
+70.1%$23.16B$2.07B100.003,900Positive News
HOLX
Hologic
4.8728 of 5 stars
$67.13
-1.7%
$78.00
+16.2%
-18.0%$14.93B$4.04B27.857,063Positive News
BAX
Baxter International
4.6523 of 5 stars
$24.58
+0.2%
$30.11
+22.5%
-36.3%$12.60B$10.64B9.7438,000
GMED
Globus Medical
4.9543 of 5 stars
$61.42
-1.8%
$87.64
+42.7%
-17.6%$8.30B$2.63B23.625,300Positive News
Analyst Revision
MASI
Masimo
4.5335 of 5 stars
$145.15
-2.3%
$193.60
+33.4%
+17.2%$7.89B$2.09B-17.045,600

Related Companies and Tools


This page (NYSE:STE) was last updated on 9/3/2025 by MarketBeat.com Staff
From Our Partners